1 recruiting, 1 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Communicable Diseases, Emerging: new trials by email Literature Review of Communicable Diseases, Emerging trials Research Report on Communicable Diseases, Emerging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial Baricitinib, Placebo - COVID-19, Emerging Infectious Disease | Phase 2 / Phase 3 | Terminated | Oslo University Hospital | 290 | 2021-06-03 | 2023-02-06 |
COVID-19 (1) · Hemorrhagic Fevers, Viral (1) · Lassa Fever (1)
Communicable Diseases (2) · Disease Attributes (2) · Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · RNA Virus Infections (2) · Virus Diseases (2) · Arenaviridae Infections (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Tract Diseases (1)
Dexamethasone (1) · Ribavirin (1) · Standard of Care (1) · baricitinib (1) · favipiravir (1)
Irrua Specialist Teaching Hospital (1) · Oslo University Hospital (1)
Austria (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Ireland (1) · Italy (1) · Liberia (1) · Luxembourg (1) · Nigeria (1) · Norway (1) · Portugal (1) · Slovakia (1)
Domique Costagliola, PhD (1) · Jose R Arribas, MD PhD (1)